These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of schizophrenia with "atypical antipsychotic drugs". Quality of life as a measure of treatment success]. Krankenpfl J; 2002; 40(7-9):230-1. PubMed ID: 12514869 [No Abstract] [Full Text] [Related]
4. Subjective well-being and quality of life under atypical antipsychotic treatment. Karow A; Naber D Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610 [TBL] [Abstract][Full Text] [Related]
5. [From neuroleptics toward antipsychotics: quality of life and schizophrenia]. Lançon C Encephale; 2003 Sep; 29(Pt 2):S43-6. PubMed ID: 14710537 [No Abstract] [Full Text] [Related]
6. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618 [TBL] [Abstract][Full Text] [Related]
7. Sertindole for the treatment of schizophrenia. Azorin JM; Kaladjian A; Fakra E; Adida M Expert Opin Pharmacother; 2010 Dec; 11(18):3053-64. PubMed ID: 21080854 [TBL] [Abstract][Full Text] [Related]
9. [Quality of life of schizophrenic patients and clozapine]. Raoul Y; Manesse P; Delage M Encephale; 1997 Sep; 23 Spec No 4():12-6. PubMed ID: 9417398 [TBL] [Abstract][Full Text] [Related]
10. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237 [TBL] [Abstract][Full Text] [Related]
13. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Weiss EM; Bilder RM; Fleischhacker WW Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611 [TBL] [Abstract][Full Text] [Related]
14. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Leucht S; Davis JM; Engel RR; Kissling W; Kane JM Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961 [TBL] [Abstract][Full Text] [Related]
15. Schizophrenia: recent advances in psychopharmacology. Sharma T Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500 [No Abstract] [Full Text] [Related]
16. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials. Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697 [TBL] [Abstract][Full Text] [Related]
18. [3 years of risperidone: from innovation to example]. Nervenarzt; 1997 Apr; 68(4 Suppl Von Der In):1-4. PubMed ID: 9442496 [No Abstract] [Full Text] [Related]
19. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion. J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380 [No Abstract] [Full Text] [Related]
20. Benefits of atypical antipsychotic medications in the treatment of psychosis. White DL Kans Nurse; 2003; 78(10):1-2. PubMed ID: 14746070 [No Abstract] [Full Text] [Related] [Next] [New Search]